Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine and Buspirone in Adults With ADHD
NCT00174226Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buspirone in attention deficit hyperactivity disorder (ADHD), sponsored by Pfizer. Started Nov 2004; status: completed.
02
Drugs
buspirone
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00174226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174226.